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czhou@med.unc.eduAbstractGlutamine is one of the main nutrients used by tumor cells for biosynthesis. Therefore,
targeted inhibition of glutamine metabolism may have anti-tumorigenic implications.
In the present study, we aimed to evaluate the effects of glutamine on ovarian cancer
cell growth. Three ovarian cancer cell lines, HEY, SKOV3, and IGROV-1, were assayed for
glutamine dependence by analyzing cytotoxicity, cell cycle progression, apoptosis, cell stress,
and glucose/glutamine metabolism. Our results revealed that administration of glutamine
increased cell proliferation in all three ovarian cancer cell lines in a dose dependent manner.
Depletion of glutamine induced reactive oxygen species and expression of endoplasmic
reticulum stress proteins. In addition, glutamine increased the activity of glutaminase (GLS)
and glutamate dehydrogenase (GDH) by modulating the mTOR/S6 and MAPK pathways.
Inhibition of mTOR activity by rapamycin or blocking S6 expression by siRNA inhibited
GDH and GLS activity, leading to a decrease in glutamine-induced cell proliferation.
These studies suggest that targeting glutamine metabolism may be a promising







(2015) 22, 577–591IntroductionOvarian cancer is the eighth most common cancer in
women worldwide, with an estimated 21 980 new cases
diagnosed and 14 270 deaths in the USA in 2014 (Siegel
et al. 2014). Ovarian cancer is the most lethal of all the
gynecologic malignancies in part due to the fact that
patients are often diagnosed with advanced stage disease
because of the absence of specific symptoms and the lack
of adequate screening tests (Mirandola et al. 2011). There
are no recognized preventative measures and no effective
screening tools for ovarian cancer (Rooth 2013).The majority of primary ovarian malignancies are derived
from epithelial cells, while w5% of ovarian carcinomas
arise from other ovarian cell types (Sung et al. 2014). The
standard of care for patients with advanced epithelial
ovarian carcinoma involves an attempt at optimal
cytoreductive surgery followed by chemotherapy with a
platinum based regimen in combination with paclitaxel.
However, although most ovarian tumors are very sensitive
to this chemotherapy regimen, the large majority of



















Research L Yuan, X Sheng et al. Glutamine in ovarian cancer 22 :4 578(Kajiyama et al. 2012, Rauh-Hain et al. 2013). Therefore,
new cytotoxic treatment strategies are urgently needed to
improve outcomes in patients with ovarian cancer.
Cancer cells have unique metabolism characteristics
such as elevated energetic and biosynthetic demands of
rapid cell growth and proliferation. The most well-known
characteristic of cancer cell metabolism is the Warburg
effect, in which cancer cells consume large amounts of
glucose through the glycolysis pathway to produce ATP and
lactate in the presence of oxygen (Bayley & Devilee 2012,
Kee & Cheong 2014). Although cancer cells exhibit high
rates of glycolysis, their mitochondrial oxidative
phosphorylation (OXPHOS) remains intact and becomes
progressively more dependent on glutamine metabolism
(Hammoudi et al. 2011). Glucose and glutamine are the two
major nutrient inputs for cancer cells as they provide
bioenergetics and intermediates for macromolecular
synthesis in proliferating cancer cells. The rate of conversion
of glutamine to lactate is higher in cancer cells than in
normal cells, which represents an alternative metabolic
pathway to glucose consumption in a glucose-limiting
environment (Helmlinger et al. 2002). The activity of
glutaminase (GLS), the first enzyme in glutaminolysis, and
glutamine level in the medium correlate with cancer cell
proliferation. Serum glutamate levels are associated with
tumor aggressiveness (Koochekpour et al. 2012). The
function of glutamine to promote cell growth is likely
dependent on their genetic and epigenetic background
(Simpson et al. 2012, Phang et al. 2013). The restriction of
glutamine induces apoptosis in melanoma and prostate
cancer cells and the inhibition of glutaminolysis by acivicin
has been shown to be very effective in the treatment of
animal models of cancer (Fu et al. 2004, 2010, Roy & Maity
2005). Inaddition, a recent studyshowedthat the inhibition
of glutamine uptake is a promising new therapeutic strategy
for treating acute myeloid leukemia (Willems et al. 2013).
However, the impact of glutamine deprivation on ovarian
cancer cell proliferation is less well characterized.
Given that glutamine metabolism is up-regulated in
cancer cells, this study aimed to investigate the effects of
glutamine on cell proliferation in ovarian cancer cells, and
determine its underlying molecular mechanisms. We
observed that depletion of glutamine inhibited cell
growth, induced significant apoptosis, caused cell cycle
G1 arrest, and induced reactive oxygen species (ROS)
production in ovarian cancer cells. Moreover, glutamine
increased cellular glycolytic activity and stimulated cell
proliferation by modulating the mTOR/S6 pathway. These
results indicate that targeting glutamine metabolism is a
promising therapeutic strategy for ovarian cancer.http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0192
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Printed in Great BritainMaterials and methods
Cell culture and reagents
The human ovarian cancer cell lines HEY, SKOV3, and
IGROV-1 were used. The HEY cells were kindly provided by
Dr McAsey of Department of Obstetrics and Gynecology
at Southern Illinois University School of Medicine. The
SKOV3 and IGROV-1 cell lines were provided by Dr Jazaeri
from the Department of Obstetrics and Gynecology,
University of Virginia. All three cell lines have been
authenticated to be ovarian cancer cell lines (Yoshioka
et al. 2012, Jazaeri et al. 2013, Xie et al. 2013, Ayyagari &
Brard 2014). The cell lines used in this study were passaged
for fewer than 6 months after resuscitation and the passage
numbers were 5–20. The HEY and IGROV-1 cell lines were
maintained in RPMI-1640 medium supplemented with 5
and 10% fetal bovine serum (FBS) respectively. The SKOV3
cell line was maintained in DMED/F12 medium supple-
mented with 10% FBS. For glutamine studies, the cells were
cultured in RPMI-1640 medium or DMED/F12 medium
without glutamine (cat #21870-076 and 12634-010, Gibco)
containing 5% dialyzed FBS and supplied with various
concentrations of glutamine. All media were supplemented
with 100 U/ml of penicillin and 100 mg/ml of streptomycin.
The cells were cultured in a humidified 5% CO2 at 37 8C.
L-glutamine was purchased from Corning Cellgro
(Manassas, VA, USA). 3-(4,5-Dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide (MTT), RNase A, bromo-
pyrvic acid (3-BP), 20,70-dichlorofluorescin diacetate (DCFH-
DA), and rapamycin were purchased from Sigma–Aldrich.
The L-Lactate Assay Kit was bought from Eton Bioscience
(SanDiego,CA,USA).2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)
amino]-2-deoxy-D-glucose (2-NBDG) and ATP assay kit
were bought from AAT Bioquest (Sunnyvale, CA, USA). The
glutamate dehydrogenase (GDH) assay kit was bought
from BioVision (Milpitas, CA, USA). The RPS6 siRNA was pur-
chased from Ambion Life Technologies. The HiperFect Trans-
fection Reagent was bought from Qiagen. Annexin-V FITC Kit
was purchased from Biolegend (San Diego, CA, USA). The
anti-GLS antibody was purchased from Abcam (Cambridge,
MA, USA), and all the other antibodies were obtained from
Cell Signaling (Danvers, MA, USA). ECL detection reagents
were purchased from GE Health care (Piscataway, NJ, USA).
All other chemicals were purchased from Sigma.Cell proliferation assay
The ovarian cancer cells, HEY, SKOV3, and IGROV-1, were


















Research L Yuan, X Sheng et al. Glutamine in ovarian cancer 22 :4 579media. After 24 h, cells were cultured in media with
different concentrations of glutamine for 48 h. Cell
proliferation was measured by adding 5 ml of MTT solution
(5 mg/ml) per well for an additional incubation of 1 h. The
MTT reaction was terminated through the replacement of
the media by 100 ml of DMSO. Viable cell densities were
determined by measuring absorbance of metabolic
conversion of the colorimetric dye at 570 nm. Each
experiment was performed in triplicate and repeated
three times to assess for consistency of results.Cell cycle analysis
Theeffectofglutamineoncell cycleprogressionwasassessed
byusing Cellometer (Wang etal. 2014; Nexcelom,Lawrence,
MA, USA). Cells were plated at a density of 1.5!105
cells/well in six-well plates overnight, and then treated
with various concentrations of glutamine for 48 h. Cells
were collected by 0.05% Trypsin (Gibco), washed with PBS
solution, fixed in a 90% methanol solution and then stored
at K20 8C until cell cycle analysiswasperformed.Onthe day
of analysis, the cells were washed with PBS and centrifuged,
resuspended in 50 ml RNase A solution (250 mg/ml) with
10 mM EDTA, followed by incubation for 30 min at 37 8C.
After incubation, 50 ml of propidium iodide (PI) staining
solution (2 mg/ml PI, 0.1 mg/ml azide, and 0.05% Triton
X-100) was added to each tube and incubated for 10 min in
the dark. The cell cycle was detected by Cellometer. The cell
cycle progression was analyzed by the FCS4 Express Software
(Molecular Devices, Sunnyvale, CA, USA).Annexin-V assay
The effect of glutamine on cell apoptosis was detected by
using Annexin-V FITC Kit. Briefly, 1.7!105 cells/well were
seeded into six-well plates overnight, and then the cells
were cultured in the media with various concentrations of
glutamine for 24 h. The cells were collected by 0.25%
Trypsin without EDTA. After PBS washing, the cells were
resuspended in 100 ml of Annexin-V and PI dual-stain
solution (0.1 mg of Annexin-V FITC and 1 mg of PI) for
15 min in the dark and detected by Cellometer. The results
were analyzed by the FCS4 Express Software. Each
experiment was repeated at least twice for consistency of
response.Glucose uptake assay
Glucose uptake assay was performed using 2-NBDG. In
brief, after cells were seeded in 96-well plates at 3000http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0192
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Printed in Great Britaincells/well in their culture media overnight, the cells were
treated in various concentrations of glutamine (0, 0.5, 2.0,
and 5.0 mM) for 24 h and then the cells were cultured with
2-NBDG (100 mg/ml) in glucose-free media with matching
concentrations of glutamine for 40 min. The 2-NBDG
uptake reaction was stopped by removing the media and
washing the cells twice with 200 ml HBSS. Fluorescence
(excitation/emissionZ485/535) was measured using a
plate reader (Tecan, Morrisville, NC, USA). Data were
normalized based on the viable cell counts measured by
the MTT assays. All the experiments were performed in
triplicate and repeated twice.L-lactate assay
L-lactate in the medium was detected by using the
L-Lactate Assay Kit. Briefly, after we treated cells with
different concentrations of glutamine for 24 h, 10 ml of the
culture medium was transferred into a new 96-well plate
and 40 ml of distilled water was added to each well.
Another 50 ml of lactate assay solution was also then
added to each well and the plates were incubated for
30 min at 37 8C without CO2. The lactate level was
measured at wavelength of 490 nm using a plate reader
from Tecan. The experiments were performed in triplicate
and repeated twice to assure consistency.ATP assay
Cellular ATP production was assessed by using Lumino-
metric ATP Assay Kit. In short, after we treated cells with
glutamine for 24 h, 90 ml/well of the ATP reaction mix was
added into the sample and mixed gently, and then
incubated for 10–20 min in the dark at room temperature.
The luminescence intensity was monitored with a plate
reader from Tecan. The ATP levels were normalized based
on the viable cell counts measured by the MTT assays.
Each experiment was performed in triplicate and repeated
twice to assess for consistency of results.ROS assay
Intracellular ROS production was detected using
DCFH-DA (Wang et al. 2014). DCFH-DA can diffuse into
cells and be deacetylated by cellular esterases to non-
fluorescent DCFH, which cannot get through membranes
freely and be rapidly oxidized to highly fluorescent DCFH
by ROS. After we finished the treatment of the cells, 10 ml
of 200 mM of DCFH-DA was added into the media and


















Research L Yuan, X Sheng et al. Glutamine in ovarian cancer 22 :4 580an excitation wavelength of 485 nm and an emission
wavelength of 530 nm using a plate reader from Tecan.
Data were normalized based on the viable cell counts
measured by the MTT assays. Each experiment was
repeated at least twice for consistency of response.GDH activity assay
Intracellular GDH activity was measured by using the
GDH assay kit. Cells were seeded into six-well plates at
1.5!105 cells/well overnight, and then the cells were
cultured in media with various concentrations of gluta-
mine for 24 h. Cell lysates were prepared in cold GDH
assay buffer. After 10–20 ml of cell lysates were transferred
into a new 96-well plate, then the GDH assay buffer was
added until the total volume was 50 ml. Composed of 82 ml
of GDH assay buffer, 8 ml of GDH developer and 10 ml of
glutameate, and 100 ml of reaction mix was added to each
well. The concentration of GDH was measured at a
wavelength of 450 nm in a plate reader after incubating
for 3 min at 37 8C. The results were normalized on the
basis of the total protein concentration of each sample.
The experiments were performed in triplicate and repeated
twice to assess for consistency of results.siRNA transfection
Transfection of siRNA was performed using Ambion RPS6
siRNA and Qiagen HiperFect Transfection Reagent. In
brief, HEY cells were plated at a density of 1!105 cells/well
in 12-well plates or 5!103 cells/well in 96-well plates. The
transfection complexes containing 137.5 ng of RPS6
siRNA and 6 ml HiperFect Transfection Reagent for
12-well plate cells or 25 ng of RPS6 siRNA and 1 ml of
HiperFect Transfection Reagent for 96-well plate cells were
added into the media. A scramble siRNA was used as the
negative control. The impact of siRNA transfection on cell
proliferation was evaluated by MTT assay. The experi-
ments were repeated twice.Western blot analysis
Total protein was extracted from ovarian cancer cells using
RIPA buffer and the protein was quantified with the BCA
Assay Kit (Thermo Scientific, Rockford, IL, USA). Protein
samples with equal loading (30 mg/well) were separated by
10–12% SDS–PAGE and transferred onto PVDF membranes.
The membranes were blocked with 5% nonfat milk and then
incubated with a 1:1000 dilution of primary antibodies
overnight at 4 8C. The membranes were washed andhttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0192
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Printed in Great Britainincubated with a secondary peroxidase-conjugeted antibody
for1 hat roomtemperature.Themembranesweredeveloped
using an enhanced ECL at Alpha Innotech Imaging System
(Protein Simple, Santa Clara, CA, USA). After developing, the
membranes were re-probed using antibody against a-tubulin
to confirm equal loading. Each experiment was repeated
at least twice for consistency of results.Statistical analysis
Data is expressed as meanGS.E.M. Data was compared using
two-tailed Student’s t-test, and P!0.05 was considered
significant.Results
Glutamine promotes cell growth in ovarian cancer cells
Glucose and glutamine are essential energy and nutrient
sources for the growth and survival of cancer cells. To verify
the effect of glutamine on the growth of ovarian cancer
cells, three ovarian cancer cell lines, HEY, SKOV3, and
IGROV-1, were treated in glutamine-free media with
various concentrations of glutamine (0, 0.5, 2.0, 5.0, and
10.0 mM) for 48 h. Cell proliferation was assessed by MTT
assay. The results showed that treatment of cells with
glutamine in the media for 48 h increased cell proliferation
by 20–50% in a dose-dependent manner. To further
validate the energy source of cell growth in ovarian cancer
cells, the three cell lines were treated with the same
concentration of glutamine in the absence of glucose in
the culture media. The results showed that increasing
concentrations of glutamine slightly increased cell prolifer-
ation in 48 h in all three cell lines (Fig. 1A, B and C). Thus,
these results confirm that glucose is a critical nutrient for
ovarian cancer cells and that glutamine promotes optimal
cell proliferation in glucose supplying conditions.
GLS catalyzes the hydrolysis of L-glutamine to
L-glutamate, which is involved in oxidation in the
mitochondria. We next investigated the impact of
glutamine on GLS protein expression using different levels
of glutamine in our ovarian cancer cells. The antibody
recognizes two transcript variants of GLS1: KGA and GAC
(Gross et al. 2014). Surprisingly, we found that treatment
of cells with glutamine for 24 h reduced the expression of
GLS in a dose-dependent manner (Fig. 1D). To further
verify the effects of glutamine on GLS expression, IGROV-
1 cells, a glutamine dependent cell line, were cultured
under glutamine starvation for 24, 36, 48, and 72 h, and
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Glutamine metabolism promotes optimal cell proliferation. Ovarian cancer
cells lines HEY (A), SKOV3 (B), and IGROV-1 (C) were treated in glutamine-
free media supplemented with various concentrations of glutamine (0, 0.5,
2.0, 5.0, and 10.0 mM) for 48 h. Cell proliferation was assessed by MTTassay.
The changes in glutaminase (GLS) expression upon the effects of glutamine
were assessed using western blot. HEY, SKOV3, and IGROV-1 cells were
treated with glutamine for 24 h. Treatment of glutamine reduced the
expression of GLS in a dose-dependent manner (D). GLS changes in IGROV-1
cells after treatment with glutamine and glutamine starvation: glutamine
starvation consistently increased the expression of GLS with the extension
of starvation, and glutamine reduced the expression of GLS with the
presence of glutamine for 48 h after starvation in IGROV-1 cells (E).
GDH activity was assayed using a GDH assay kit in IGROV-1 cells. Glutamine



















Research L Yuan, X Sheng et al. Glutamine in ovarian cancer 22 :4 581growth medium for 24 and 48 h. The results of western
blot showed that glutamine starvation consistently
increased the expression of GLS with the extension of
starvation, and treatment of glutamine for 24 h increased
the expression of GLS protein whereas glutamine reduced
the expression of GLS after 48 h treatment at either 24 or
48 h starvation (Fig. 1E). Thus, these results indicate that
the role of GLS in glutamine conversion is a rate-limiting
process, and the activity of GLS controlled the flux of
glutaminolysis (Qie et al. 2014). To help validate these
results, we further assessed the activity of GDH in the
presence or absence of glutamine. GDH converts
glutamate to a-ketoglutarate in glutamine catabolism.
We observed that there is a strong correlation between
increased GDH activity and presence of glutamine after
24 h of treatment (Fig. 1F). These results suggest that
glutamine promotes glutaminolysis, which supports cell
growth in ovarian cancer cells.http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0192
q 2015 The authors
Printed in Great BritainGlutamine regulates cell cycle and apoptosis in ovarian
cancer cells
To elucidate the mechanisms of glutamine on cell growth,
the effects of glutamine on cell cycle progression were
analyzed. The three ovarian cancer cell lines were cultured
with various concentrations of glutamine (0, 0.5, 2.0, and
5.0 mM) for 48 h, and the cell cycle changes were analyzed
using Cellometer. The results showed that depletion of
glutamine induced cell cycle G1 arrest in the three cell
lines. The S phase gradually increased with increasing
concentrations of glutamine in the three cell lines
(Fig. 2A, B and C). These results indicated that glutamine
promoted cell growth by inducing cell cycle changes.
We further investigated the effects of glutamine on cell
cycle checkpoints. Cyclin D1 activates CDK4 and promotes
the passage of the cell into S phase from G1, and p21 is a key
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Glutamine affects cell cycle progression. HEY (A), SKOV3 (B), and IGROV-1
(C) cells were treated in glutamine-free media supplemented with various
concentrations of glutamine (0, 0.5, 2.0, and 5.0 mM) for 48 h. Cell cycle
analysis was performed using Cellometer. Depletion of glutamine induced
cell cycle G1 phase arrest in ovarian cancer cells. The effects of glutamine on
cyclin D1, CDK4, and p21 were examined by western blotting in HEY (D),



















Research L Yuan, X Sheng et al. Glutamine in ovarian cancer 22 :4 582The results of western blot showed that the expressions of
both cyclin D1 and CDK4 increased, and p21 decreased
with increasing glutamine concentrations for 24 h (Fig. 2D,
E and F). These results suggest that glutamine promotes the
passage of cells into S phase from G1.
Finally, we evaluated the effects of glutamine on cell
apoptosis using Annexin-V assay. Annexin-V binds to
phosphaticylserine externalized on the surface of the cell
membrane, which is a distinct phenomenon of early
apoptosis (Schointuch et al. 2014). The percentage of
apoptotic cells increased distinctly in glutamine-free media
in all three cell lines after 24 h of treatment (Fig. 3A,B and C),
suggesting that depletion of glutamine in regular media
could induce significant apoptosis in ovarian cancer cells.Glutamine deprivation induces cell stress
Increased ROS is an index of intracellular oxidative stress.
To investigate whether different concentrations of gluta-
mine induced cell stress, we determined the effects of
glutamine on ROS production using DCFH-DA assay.http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0192
q 2015 The authors
Printed in Great BritainThe depletion of glutamine greatly increased ROS pro-
duction by 1.5- to 3.6-fold in the three cell lines after 24 h.
The addition of glutamine in the media markedly reduced
ROS production (Fig. 4A). We then analyzed the changes
in proteins related to cell stress, including protein kinase-
like endoplasmic reticulum kinase (PERK), poly (ADP-
ribose) polymerase (PARP), Calnexin, and Bip using
western blotting after the cells were treated with different
concentrations of glutamine for 24 h. The data showed
that depletion of glutamine enhanced the expression of
PERK, PARP, Bip, and Calnexin, but the expression of these
proteins significantly decreased in the presence of gluta-
mine (Fig. 4B, C and D). These results indicate that
glutamine reduces intracellular oxidative stress and ER
stress induced by depletion of glutamine.Glutamine complements ATP production on the basis
of glycolysis
To investigate the effects of glutamine metabolism on
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Figure 3
Depletion of glutamine induces cell apoptosis. HEY (A), SKOV3 (B), and
IGROV-1 (C) cells were cultured with different concentrations of glutamine
for 24 h. The apoptosis were detected using an Annexin-V FITC Kit.
Depletion of glutamine induced significant cell apoptosis in the three


















Research L Yuan, X Sheng et al. Glutamine in ovarian cancer 22 :4 583cultured with various concentrations of glutamine for
24 h, and cellular glucose uptake was detected with
2-NBDG fluorescence assay. The results indicated that
glutamine increased glucose uptake in our ovarian cancer




























































Depletion of glutamine induces cell stress. The three cell lines were treated
with glutamine for 24 h. The production of intracellular reactive oxygen
species (ROS) was detected using DCFH-DA. Depletion of glutamine greatly
http://erc.endocrinology-journals.org
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Printed in Great Britainglutamine on energy flux. The levels of cellular ATP were
analyzed using luminometric ATP assay after cells were
treated with various concentrations of glutamine for 24 h.
Our data showed that glutamine increased cellular ATP
production (Fig. 5B). Given that lactate is an importantC D
in




































































increased ROS production (A). The expression of stress proteins in cells was
detected using western blotting. Glutamine reduced the expression of
stress proteins in HEY (B), SKOV3 (C), and IGROV-1 (D). *P!0.05.
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Glutamine complements ATP production. The cells were cultured in media
with various concentrations of glutamine for 24 h. The levels of cellular
glucose uptake (A), cellular ATP production (B), and lactate in the media (C)
were detected. The cells were treated with compound 968 or 3-BP for 24 h
in 2.0 mM glutamine or glutamine-free media respectively. The levels of
ATP (D) and lactate (E) were detected by ELISA assay. The expression of
glycolytic proteins was detected by western blotting in HEY (F), SKOV3 (G),


















Research L Yuan, X Sheng et al. Glutamine in ovarian cancer 22 :4 584product of glycolysis and the main source of energy for
cancer cells, the effects of glutamine on lactate production
were assessed under the same culture condition as ATP
assay. The results indicated that the lactate in the culture
media slightly increased upon exposure to glutamine
(Fig. 5C). Compound 968, a GLS inhibitor, and 3-BP, a
glycolysis inhibitor, were used to treat cells for 24 h, and
cellular ATP and lactate levels in the media were assayed.
ATP production markedly decreased by the inhibition of
either glutaminolysis or glycolysis, and the inhibition of
glycolysis reduced ATP production more profoundly in
glutamine-free media than that in 2.0 mM glutamine
media in all three cell lines (Fig. 5D). The inhibition of
glutaminolysis or glycolysis slightly reduced lactate
production in the presence or absence of glutamine
(Fig. 5E). These results suggest that glucose and glutaminehttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0192
q 2015 The authors
Printed in Great Britainwere major energy sources, and glutamine supported
cellular ATP production in the presence of glycolysis in
ovarian cancer cells.
We also analyzed the expression of key glycolytic
proteins in the presence and absence of glutamine. We
treated cells with different concentrations of glutamine for
24 h. The expression levels of hexokinase 1 (HK1), platelet-
type phosphofructokinase (PFKP), pyruvate kinase M 1/2
(PKM1/2), and pyruvate dehydrogenase (PDH) were
analyzed using Western blotting. The results showed
that HK1 and PFKP either increased or demonstrated
minimal changes in HEY and SKOV3 cells, whereas HK1
increased and PFKP decreased in IGROV-1 cells. PKM1/2
and PDH exhibited different changes after glutamine
treatment for 24 h (Fig. 5F, G and H). These results suggest


















Research L Yuan, X Sheng et al. Glutamine in ovarian cancer 22 :4 585the changes in the glycolytic proteins are mainly
dependent on different cell types.Glutamine activates the MAPK and mTOR/S6 pathways
Activation of the MAPK and phosphatidylinositol 3
kinase/Akt/mTOR pathways plays a crucial role in the
control of cell growth and survival in ovarian cancer, and
inhibition of these pathways leads to the inhibition of
ovarian cancer growth. To investigate the mechanisms
underlying the regulation of cell growth by glutamine, we
characterized the effect of glutamine on the MAPK and
mTOR/S6 signaling pathways. Glutamine increased phos-
phorylation of S6 (Ser235/236) and p42/44 (ERK) in a dose-
dependent manner in ovarian cancer cells within 24 h of
exposure (Fig. 6A, B, C, D and E). These results indicate
that the MAPK/ERK and mTOR/S6 pathways were
involved in glutamine metabolism.Glutamine promotes cell growth via the mTOR/S6
pathway
Given that glutamine strongly increased the expression of
phosphorylation of S6, we investigated the relationship
between the mTOR/S6 pathway and glutamine metab-
olism. First, we treated the three ovarian cancer cell lines
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Figure 6
Glutamine activates the MAPK and mTOR/S6 pathways. The expression of
phosphorylation of p-42/44 and p-S6 in HEY (A), SKOV3 (B), and IGROV-1
(C) cells was detected by western blotting after treatment with glutamine
http://erc.endocrinology-journals.org
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Printed in Great Britainand 10 nmol/l), an mTOR inhibitor, in regular media for
24 h. The results of Western blotting showed that
rapamycin strongly inhibited the expression of phos-
phorylation-S6 and reduced GLS expression in a dose-
dependent manner (Fig. 7A, B and C). GDH activity assay
also showed that rapamycin inhibited GDH activity after
24 h of treatment (Fig. 7D). We next treated cells with
rapamycin in the presence or absence of glutamine
conditions for 60 h to access cell proliferation. The results
showed that rapamycin significantly inhibited cell
proliferation and blocked the phosphorylation of S6 and
expression of GLS induced by glutamine (Fig. 7E–H).
To further confirm the role of the mTOR/S6 pathway
in glutaminolysis, we transfected S6 siRNA into HEY cells
to knockdown S6 protein expression. After 24 h of
transfection, western blot showed that S6 siRNA effec-
tively inhibited the phosphorylation of S6 (Fig. 8A). We
then treated cells with glutamine for 24 h after siRNA
transfection. The results of western blot showed that
siRNA transfection inhibited the phosphorylation of S6
induced by glutamine (Fig. 8B). We further analyzed the
activity of GDH, and found that siRNA transfection
markedly reduced GDH activity in HEY cells treated with
glutamine (Fig. 8C). Finally, we transfected S6 siRNA into
HEY cells in 96-well plates, and the cells were treated with
glutamine for 48 h. MTT assay showed that S6 siRNA



































for 24 h. Glutamine increased protein expression of p-42/44 and p-S6 in the
ovarian cancer cells (D and E).
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Rapamycin inhibits glutaminolysis in ovarian cancer cells. HEY (A), SKOV3
(B), and IGROV-1 (C) cells were treated with various concentrations of
rapamycin as indicated in their regular media for 24 h. Treatment with
rapamycin reduced the expression of GLS and phosphorylation of p-S6.
Rapamycin inhibited GDH activity in HEY cells (D) and blocked the cell
proliferation induced by glutamine in the ovarian cancer cells after
60 h treatment (E). Western blotting showed rapamycin inhibited the
expression of phosphorylation of p-S6 and GLS induced by glutamine in


















Research L Yuan, X Sheng et al. Glutamine in ovarian cancer 22 :4 586glutamine (Fig. 8D). These data suggest that glutamine
metabolism is dependent on the mTOR/S6 pathway, and
S6 protein is a key component involved in cell prolifer-
ation induced by glutamine in our ovarian cancer cells.Discussion
Even though glutamine is the most common amino acid
in tissues and plasma and represents a major source of
carbon and energy in cancer cells, no previous reports
focus on glutamine metabolism in ovarian cancer cells
from a therapeutic perspective. In this study, we investi-
gated the potential mechanism of glutamine in modulat-
ing cell growth in human ovarian cancer cells. Our results
showed that compared with glutamine deprivation,http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0192
q 2015 The authors
Printed in Great Britainadministration of glutamine improved cell proliferation
through the mTOR/S6 pathway, inhibited apoptosis and
cell stress subjected to depletion of glutamine, and altered
glycolytic activity, which led to increased ATP and lactate
production. These results are consistent with the view
that targeting glutamine metabolism with molecular
intervention may be used as an effective strategy for
ovarian cancer therapy.
Understanding the effects of Glutamine deprivation
on cell growth is necessary for full appreciation of the
importance of glutamine metabolism to maintain cancer
cell survival. Given that glutamine deprivation has been
shown to decrease cell proliferation, DNA and protein
synthesis in hepatocellular, prostate, breast and cervical







































































































































































































































Knockdown S6 by siRNA transfection reduces the expression of GLS and
activity of GDH. HEY cells were transfected with RPS6 siRNA for 24 h.
Western blotting showed the expression of phosphorylation of S6 was
inhibited after siRNA transfection (A). HEY cells were treated with 2.0 mM
glutamine for 24 h after siRNA transfection. Both of S6 siRNA and
rapamycin reduced the expression levels of GLS and phosphorylation of S6
(B). S6 siRNA transfection decreased GDH activity induced by glutamine (C).
HEY cells were treated with 2.0 mM glutamine for 48 h after siRNA


















Research L Yuan, X Sheng et al. Glutamine in ovarian cancer 22 :4 587Dang 2010, Ko et al. 2011), we chose to evaluate the
possible role of glutamine deprivation on triggering of the
cell cycle arrest and apoptosis. The impact of glutamine
deprivation on cancer cell cycle progression and apoptosis
is less well characterized. Recent in vitro studies have
provided evidence that there are differential responses of
cancer cells to glutamine deprivation under different
genetic and epigenetic background (Collins et al. 1998,
Simpson et al. 2012, Hensley et al. 2013, Phang et al. 2013).
Cancer cells and transformed cells with c-Myc over-
expression undergo apoptosis in response to glutamine
limitation by intrinsic and/or extrinsic pathways depend-
ing on the cell type (Yuneva et al. 2007, Qing et al. 2012).
The depletion of glutamine induced G1 phase arrest in
breast and prostate cancer cells, while K-Ras-driven
cancer cells and transformed cells arrested in either S- or
G2/M-phase alone, with the changes triggered by gluta-
mine deprivation (Thornthwaite & Allen 1980, Fu et al.
2003, Saqcena et al. 2013, 2015). In this study, wehttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0192
q 2015 The authors
Printed in Great Britainexamined changes in the cell cycle and apoptosis in the
three cell lines treated with different concentrations of
glutamine for 24 h. Our results demonstrated that
depletion of glutamine inhibited cell proliferation in the
ovarian cancer cells via increased Annexin-V expression
(Fig. 3A, B and C), and induced cell cycle G1 arrest (Fig. 2A,
B and C). As a result, the expressions of cyclin D and CDK4
were down-regulated, whereas p21 was strongly enhanced
(Fig. 2D, E and F), thus establishing the conditions that
brought cells to a G1 cell cycle arrest. These results indicate
that the anti-proliferative effects exerted by glutamine
deprivation can be attributed to the induction of cell cycle
arrest and apoptosis.
The active cells are constantly exposed to the natural
byproducts of normal metabolism of oxygen, notably
ROS, which activate signaling events that facilitate both
normal and cancer cell proliferation (Weinberg et al.
2010). The elevated ROS productions may cause cell


















Research L Yuan, X Sheng et al. Glutamine in ovarian cancer 22 :4 588structures and functions. Glutamine is involved in
antioxidant defense function in cells by increasing
glutathione (GSH) levels, decreasing ROS levels and
providing a source of NADPH, which in turn protects
cells from oxidative stress (Shanware et al. 2011).
Depletion of Glutamine has been previously found to
increase the generation of ROS and reduce GSH levels in
prostate cancer cells (Fu et al. 2006, Liu et al. 2011).
Administration of Glutamine attenuated oxidative stress
and ER stress in rats with 2,4,6-trinitrobenzene sulfonic
acid induced colitis (Crespo et al. 2012). After treating our
ovarian cancer cells with different concentrations of
glutamine, we first found that glutamine resulted in
decreased ROS levels induced by depletion of glutamine
and was accompanied by decreased expression of ER stress
markers including Calnexin, Bip, PERK, and PARP after
24 h of treatment (Fig. 4A, B, C and D). This suggests that
glutamine has a function in protecting against the cell
stress induced by glutamine restriction or other stress
inducers. It has been reported that knockdown GLS2 (GLS)
by siRNA increased ROS production and oxidative DNA
damage in colon cancer cells and elevated GLS2
expression was necessary for cells to maintain intracellular
levels of glutamate, a-ketoglutarate, GSH, and ROS (Hu
et al. 2010, Suzuki et al. 2010). The complexity of both
oxidative stress and ER stress and the mechanisms by
which depletion of glutamine induced both stresses
provide opportunities for further investigation.
Oxidation of glutamine’s carbon backbone in the
mitochondria is a major metabolic function of glutamine
and a primary source of energy for proliferating cells in
some cancer cells (DeBerardinis & Cheng 2010). Glycolysis
and mitochondrial OXPHOS are two tightly coupled
processes. The point of balance between glycolysis and
OXPHOS fluctuates depending on the changes in their
microenvironment and the genetic make-up of a cancer
cell. Cancer cells maintain a significant level of OXPHOS
capacity to rapidly switch from glycolysis to OXPHOS
during carcinogenesis and cell energy stress (Antico
Arciuch et al. 2013, Billiard et al. 2013). Glutamine
deprivation increased glucose consumption, elevated
PDH activity and decreased cellular ATP production in
prostate cancer cells. Similar results have been obtained in
pancreatic cancer cells and human embryonic kidney cells
(HA1ER) with glutamine stimulating glucose uptake
(Kaadige et al. 2009). Glutamine deprivation likely reduces
the availability of glutamate and a-ketoglutarate in the
TCA cycle, leading to a compensatory increase in the
activity of aerobic glycolysis. In this study, we investigated
the effect of glutamine on glycolysis in ovarian cancerhttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0192
q 2015 The authors
Printed in Great Britaincells. While decreasing both glucose uptake and cellular
ATP, we discovered that depletion of glutamine increased
GLS protein expression in a time dependent manner and
the expressions of glycolytic proteins induced by gluta-
mine was diverse after 24 h of treatment of glutamine in
three ovarian cancer cell lines. These divergent effects may
be a consequence of the different genetic backgrounds in
response to different glutamine concentrations for 24 h in
our cell lines. This raises the possibility that the complex
metabolic coordination between glucose and glutamine
metabolism observed in ovarian cancer cells is the result of
genetic mutations, presumably specific to cell type
(DeBerardinis & Cheng 2010).
Constitutively activated proliferative signaling
pathways via genetic mutations have been recognized as
a major driver for carcinogenesis in ovarian cancer
(hAinmhire et al. 2014). The AKT/mTOR and MAPK
pathways seem to be major pathways involved in the
regulation of cell proliferation, invasion and bioenergetics
by glutamine in some cancers including ovarian cancer
(Yang et al. 2014). Glutamine stimulates the proliferation
of pTr cells and regulates intestinal permeability and
protein synthesis in intestinal epithelial cell through
mTOR /S6 signal transduction pathway (Boukhettala
et al. 2012, Kim et al. 2013). Additional evidence shows
that glutamine flux regulates mTOR activation through
facilitating the uptake of leucine (Nicklin et al. 2009).
Studies on the regulation of cell proliferation by glutamine
in the MAPK pathway are controversial (Nicklin et al.
2009). Previous studies demonstrated inhibition of the
MEK/ERK pathway interfered with glucose metabolism but
not glutamine metabolism (Traves et al. 2012). However,
glutamine promoted growth, migration, and differen-
tiation in HDPCs cells through activated MAPK pathway
(Kim et al. 2014). The connection between mTOR/S6 and
MAPK signal transduction pathways related to glutamine
metabolism is unknown. In order to determine the effects
of glutamine on the mTOR/S6 and MAPK pathways, we
detected changes in the phosphorylation of ribosomal
protein S6, targets of AKT/mTOR, and phosphorylation of
p42/44, a key protein in MAPK pathway. Increased
phosphorylated S6 and phosphorylated p42/44 protein
expressions were observed in the three cell lines after
treatment with glutamine for 24 h (Fig. 6A, B, C, D and E),
indicating the positive effects of mTOR/S6 and MAPK
signaling pathways on cell proliferation in response to
glutamine in ovarian cancer cells. We further demon-
strated that inhibition of mTOR by rapamycin decreased
the expression of GLS protein and activity of GDH and


















Research L Yuan, X Sheng et al. Glutamine in ovarian cancer 22 :4 589three cell lines (Fig. 7A, B, C, D, E, F, G and H). Knockdown
of S6 by siRNA showed that S6 is involved in the regulatory
mechanism of glutamine metabolism for cell growth
through GLS and GDH activities (Fig. 8B, C and D). Our
results are consistent with previously published data,
which confirmed that the mTOR pathway regulated
glutamine metabolism by promoting the activity of GDH
that required transcriptional repression of SIRT4 (Csibi
et al. 2013).
In conclusion, the present study provides the first
detailed comprehensive analysis of glutamine on cell
proliferation, glycolysis, cell cycle and apoptosis, cell
stress, energy flux and mTOR/S6 signaling pathways in
ovarian cancer cells. Our results indicate that glutamine
promotes cell growth by activating the mTOR/S6 and
MAPK pathways. Therefore, based on the preliminary data
generated by these studies, we believe that targeting
glutamine metabolism might prove a valuable novel
therapeutic strategy for ovarian cancer therapy.Declaration of interest
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